SHORTList
Proxima logo
AI/ML
Biotech/Pharma
HealthTech

Proxima

AI-native biotech for proximity-based therapeutics

Boston· 4 rolesNew York· 4 rolesZurich· 3 roles

CORE INFO

$91.45M
Total Funding
Seed
Round
2019
Founded
New York, NY
Headquarters

Proxima is a biotechnology company that leverages AI to develop proximity-based therapeutics, targeting previously undruggable diseases. Their innovative approach appeals to biopharmaceutical companies seeking advanced drug discovery solutions.

  • Proxima raised $80 million in a seed funding round led by DCVC, with participation from NVentures and other strategic investors.bloomberg.com
  • Proxima has established significant research collaborations with Johnson & Johnson and Bristol Myers Squibb.finsmes.com
  • Bloomberg reported on Proxima's $80 million funding round, highlighting the investment from prominent tech and venture capital firms.bloomberg.com

WHY WE WOULD WORK AT PROXIMA

Transform Medicine

Join a mission to unlock a new chapter in medicine by making protein interactions programmable, addressing previously undruggable disease targets.

Innovative Technology

Work with cutting-edge AI and NeoLink data-generation technology to design proximity-based small molecules like molecular glues and PROTACs.

Strategic Collaborations

Collaborate with industry giants like Johnson & Johnson and Bristol Myers Squibb, contributing to multibillion-dollar research initiatives.

Growth Opportunities

Be part of a rapidly growing startup that raised $80 million in seed funding to scale its innovative therapeutic solutions.

Impactful Work

Contribute to groundbreaking research in oncology and immunology, with programs advancing toward clinical trials as early as 2026.

Dynamic Team Culture

Join a passionate team of experts dedicated to revolutionizing drug discovery and fostering a collaborative and innovative work environment.

MARKET AND TRACTION

TOTAL ADDRESSABLE MARKET

  • Proxima operates within the biopharmaceutical industry, focusing on drug discovery and development.

  • The company specifically targets areas such as oncology and immunology, which represent significant market opportunities for innovative therapeutic solutions.

  • Proxima's approach aims to address previously undruggable disease targets, expanding the potential market for its proximity-based therapeutics.

    • NOTABLE CUSTOMERS

  • Proxima has established multibillion-dollar research collaborations with leading biopharmaceutical companies.

  • Notable partners include Johnson & Johnson, Bristol Myers Squibb, and Blueprint Medicines (acquired by Sanofi), highlighting the company's strong position in the industry.

    • KEY METRICS

    ✦ KEY METRIC
  • Proxima has raised a total of $91.45 million in funding since its inception.

  • The most recent funding round was an $80 million seed round led by DCVC, announced on January 13, 2026.

  • Multiple co-developed programs with partners are advancing toward the clinic, with the first on track to enter clinical trials in 2026.

    • GROWTH TACTICS

  • Proxima integrates proteome-scale structural data with advanced AI through its NeoLink data-generation technology and Neo AI models.

  • The company focuses on the end-to-end discovery and rational design of proximity-based small molecules, including molecular glues and PROTACs, to enhance its therapeutic offerings.

  • Strategic collaborations with major biopharmaceutical firms are a key tactic for advancing research and development efforts.

    • COMPETITIVE ADVANTAGE

  • Proxima's AI-native approach to drug discovery allows for the programmable manipulation of protein interactions, setting it apart from traditional biotech methods.

  • The integration of advanced AI with structural data positions Proxima to tackle complex and previously undruggable disease targets effectively.

  • Collaborations with industry leaders enhance Proxima's credibility and access to resources, further solidifying its competitive edge in the market.

    • PRODUCT AND TECH

    NeoLink Data-Generation Technology

    NeoLink is Proxima's advanced data-generation technology that integrates proteome-scale structural data with AI, enabling the end-to-end discovery and rational design of proximity-based small molecules.

    Neo AI Models

    Proxima's Neo AI models leverage artificial intelligence to analyze complex protein interactions, facilitating the development of innovative therapeutic strategies targeting previously undruggable diseases.

    Proximity-Based Therapeutics

    Proxima specializes in the development of proximity-based therapeutics, including molecular glues and PROTACs, which aim to modulate protein interactions for novel treatment approaches in oncology and immunology.

    Collaborative Research Partnerships

    Proxima has established significant collaborations with leading biopharmaceutical companies like Johnson & Johnson and Bristol Myers Squibb, enhancing its research capabilities and accelerating the path to clinical trials.

    Programmable Protein Interactions

    The company's mission focuses on making protein interactions programmable, which is crucial for creating targeted therapies that can induce, modulate, or block specific protein interfaces.

    COMPANY CULTURE

    Values

  • Innovation in drug discovery

  • Commitment to addressing undruggable disease targets

  • Collaboration with leading biopharmaceutical companies

  • Emphasis on AI-driven solutions

  • Integrity in scientific research

    • Operating Principles

  • Focus on proximity-based therapeutics

  • Integration of proteome-scale structural data with AI

  • End-to-end discovery and rational design of small molecules

  • Agile response to scientific challenges

  • Continuous improvement through feedback and learning

    • Benefits

  • Opportunity to work on groundbreaking therapeutic strategies

  • Collaborative environment with industry leaders

  • Access to advanced AI technologies

  • Potential for significant impact on patient outcomes

  • Support for professional development and growth

    • Learning & Growth

  • Encouragement of continuous learning and innovation

  • Opportunities for mentorship from industry experts

  • Regular training on new technologies and methodologies

  • Participation in scientific conferences and workshops

  • Fostering a culture of knowledge sharing

    • Team Cadence

  • Regular team meetings to align on goals

  • Collaborative project-based work

  • Open communication channels for feedback

  • Flexibility in work arrangements to enhance productivity

  • Celebrating milestones and achievements together

    • HIRING SIGNAL

    11
    Open roles on their careers page
    Snapshot via live ATS poll
    —
    Net new roles in the last 90 days
    Available once weekly history accrues
    90-Day VelocityV2 · BACKFILL
    Trend builds weekly as historical rows accrue
    By Function
    Breakdown of open roles
    Other · 7
    Operations · 2
    Engineering · 2
    Top Locations
    Where hiring is concentrated
    Remote-eligible postings counted separately
    Boston
    4
    New York
    4
    Zurich
    3
    SourcesGreenhouseLeverAshbyWorkableSmartRecruitersRipplingRecruiteeFallback · Wellfound, YC Work-at-a-Startup, careers-page scrape

    KEY COMPANY ANNOUNCEMENTS

    Filter
    9 announcements · ranked by importance
    Jun 10, 2026FUNDINGForm D filing — Proxima Bio, Inc. (CIK 0002104665)sec.gov
    Jan 13, 2026FUNDINGProxima Raises $80 Million for AI Drug Design From DCVC, Nvidia - Bloombergbloomberg.com
    Jan 13, 2026FUNDINGProxima Raises $80 Million Led by DCVC to Power the Next Generation of Proximity-Based Medicinesbusinesswire.com
    Jan 13, 2026FUNDINGProxima Raises $80M in Seed Fundingfinsmes.com
    Nov 21, 2024FUNDINGForm D filing — Type One Proxima LLC (CIK 0002045086)sec.gov
    Sep 24, 2024FUNDINGForm D filing — Proxima, Inc. (CIK 0002037517)sec.gov
    Oct 1, 2023FUNDINGProxima Closes $80M Seed Round to Advance Quest for ‘Proximity’ Drugs | citybizcitybiz.co
    Mar 5, 2026EXEC HIREProxima Appoints Raymond Deshaies, Lyn Jones and Juri Rappsilber to Scientific Advisory Board | FirstWord Pharmafirstwordpharma.com
    Oct 1, 2023PRESSProxima Bio | Early-Stage NYC AI Startup | AI Atlas NYCaiatlas.nyc